Writer of the article:
Printed Could 13, 2024 • 4 minute learn
Article content material
Knowledge highlights potential of Hummingbird Bioscience’s dual-payload antibody-drug conjugate platform to enhance upon the present era of ADCs
SAN FRANCISCO and SINGAPORE, Could 13, 2024 (GLOBE NEWSWIRE) — Hummingbird Bioscience, a precision biotherapeutics firm discovering and growing transformative biologics for hard-to-treat ailments, right this moment introduced two shows on the 20th Annual PEGS Boston summit being held from Could 13-17, 2024. Knowledge from the primary presentation demonstrates the flexibility to direct antibodies and antibody-drug conjugates (ADCs) to rationally chosen epitopes of curiosity on difficult disease-associated proteins. Knowledge from the second presentation present how a novel dual-payload ADC method has the potential to deal with resistance and enhance the therapeutic window of ADCs.
Commercial 2
Article content material
Article content material
“The information introduced at PEGS present for the primary time how our proprietary fourth era antibody-drug conjugate (ADC) platform leverages novel linker and dual-payload applied sciences to beat the resistance noticed with earlier era single payload ADCs. Our ADC expertise has the potential to deal with a lot of sufferers which have both intrinsic or acquired resistance to at the moment accredited ADCs,” mentioned Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer, Hummingbird Bioscience. “We may even showcase how our proprietary Rational Antibody Discovery platform engineers immune responses in transgenic mice fashions in order that ensuing ADCs and antibodies bind to the important thing epitopes on disease-associated proteins for optimum drug properties. These information proceed to assist our perception that our next-generation ADC platform can generate best-in-class ADCs that deal with payload resistance, optimize tumor specificity, and improve payload supply, and subsequently maximize the anti-tumor potential of ADCs.”
Presentation particulars:
Title: Engineering Immune Responses for Epitope-Centered Antibody Discovery
Presenter: Jerome Boyd-Kirkup, Ph.D., Chief Scientific Officer
Session: Show of Biologics – Novel Platforms
Date/Time: Monday, Could 13, 2024, 1:45 p.m. ET
Prime Tales
Article content material
Commercial 3
Article content material
Title: Overcoming Payload Resistance with Twin-Payload ADCs
Presenter: Ben Ayers, DPhil, Vice President, Antibody-Drug Conjugates
Session: Driving Scientific Success in Antibody Drug Conjugates – Novel payloads and MOAs
Date/Time: Friday, Could 17, 2024, 9:30 a.m. ET
About Hummingbird Bioscience’s ADC Platform
The 4th era ADC platform developed by Hummingbird Bioscience goals to deal with the important thing limitations in efficacy and security of present accredited ADCs. The ADC platform combines the corporate’s AI-enabled Rational Antibody Discovery Platform and proprietary linker and dual-payload applied sciences to unlock the ability of dual-payload approaches towards a very powerful disease-associated proteins. The platform engineers doubtlessly best-in-class ADCs that deal with payload resistance, optimize payload supply and tumor specificity, and maximize anti-tumor cytotoxic potential.
About Hummingbird Bioscience’s Rational Antibody Discovery Platform
The Rational Antibody Discovery (RAD) platform is designed to deal with the challenges of conventional antibody approaches. This expertise permits the corporate to determine important practical areas of a goal protein utilizing mAbPredict, a machine learning-enabled expertise platform that identifies optimum areas to focus on, after which drives manufacturing of antibodies towards these epitopes utilizing mAbHits, a proprietary immuno-engineering expertise that directs the antibody response to pre-determined epitopes of curiosity within the proprietary transgenic HMBD Abvantage mouse. In contrast to classical approaches to antibody discovery which have restricted management over antibody binding areas, and therefore, skill to focus on optimum epitopes, mAbHits ensures in vivo era and affinity maturation of antibodies towards solely the optimum epitope. This systematic and rational method to antibody discovery opens up the potential of discovering antibodies to particular areas of many necessary “onerous targets” that haven’t been drugged or are inadequately drugged up to now. The RAD platform has produced a number of antibodies and ADCs that successfully goal disease-associated proteins, together with two antibodies which can be at the moment in Section I trials (HMBD-001 and HMBD-002) and a not too long ago out-licensed ADC (HMBD-501) that may enter the clinic in 2024.
Commercial 4
Article content material
About Hummingbird Bioscience
Hummingbird Bioscience is a precision biotherapeutics firm discovering and growing transformative biologics for hard-to-treat ailments. To handle key challenges with present antibody-drug conjugate (ADC) therapies, Hummingbird Bioscience is constructing a pipeline of next-generation ADCs utilizing its proprietary antibody discovery and linker/payload platforms. The corporate has a pipeline of ADCs in preclinical improvement and different novel biologics together with monoclonal antibodies, HMBD-001 (anti-HER3 mAb) and HMBD-002 (anti-VISTA mAb) in Section I and a not too long ago out-licensed ADC (HMBD-501) that may enter the clinic this yr. The Hummingbird Bioscience method combines computational and techniques biology with moist lab drug discovery in a multi-disciplinary, collaborative atmosphere spanning preliminary discovery by means of medical improvement. The corporate harnesses this built-in method throughout goal identification and affected person choice, enabling the crew to extend the effectivity of translating novel scientific insights whereas lowering the inherent threat in drug discovery and improvement. At Hummingbird Bioscience, the dedication to rigorous science, teamwork, and mental integrity underpins our ardour to speed up the journey of latest medicine from idea to clinic.
For extra data, please go to www.hummingbirdbioscience.com, and observe Hummingbird Bioscience on LinkedIn, X (previously Twitter), and YouTube.
Contacts:
Media
Crystal Ho
c.ho@hummingbirdbio.com
media@hummingbirdbio.com
+65 6979 5580
Traders
buyers@hummingbirdbio.com
Article content material
